Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats

European Journal of Neuroscience

Volumn 33, Issue 12, 2011, Pages 2247-2254

  Papathanou, Maria ^a   Rose, Sarah ^b   Mccreary, Andrew ^c   Jenner, Peter ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Chemical Design and Synthesis Unit   (Netherlands)

Author keywords

Abnormal involuntary movements; Continuous dopaminergic stimulation; Dopamine agonists; L Dopa; Parkinson's disease

Indexed keywords

APOMORPHINE; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; LEVODOPA; OXIDOPAMINE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DYSKINESIA; INVOLUNTARY MOVEMENT; MALE; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STOMACH EMPTYING;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; MALE; OXIDOPAMINE; RATS; RATS, WISTAR;

EID: 80955180002     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2011.07704.x     Document Type: Article

References (50)

1. Barone, P., Bravi, D., Bermejo-Pareja, F., Marconi, R., Kulisevsky, J., Malagu, S., Weiser, R. & Rost, N. (1999) Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology, 53, 573-579.
2. Bezard, E. (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci., 21, 6853-6861.
3. Blanchet, P., Bedard, P.J., Britton, D.R. & Kebabian, J.W. (1993) Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine- exposed monkeys. J. Pharmacol. Exp. Ther., 267, 275-279.
4. Blanchet, P.J., Gomez-Mancilla, B. & Bedard, P.J. (1995) DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. J. Neural Transm. Suppl., 45, 103-112.
5. Bonuccelli, U., Colzi, A. & Del Dotto, P. (2002) Pergolide in the treatment of patients with early and advanced Parkinson's disease [Review]. Clin. Neuropharmacol., 25, 1-10.
6. Boyce, S., Rupniak, N.M., Steventon, M.J. & Iversen, S.D. (1990) Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin. Neuropharmacol., 13, 448-458.
7. Bracco, F., Battaglia, A., Chouza, C., Dupont, E., Gershanik, O., Marti Masso, J.F. & Montastruc, J.L. (2004) The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS. Drugs, 18, 733-746.
8. Carlsson, T., Winkler, C., Burger, C., Muzyczka, N., Mandel, R.J., Cenci, A., Bjorklund, A. & Kirik, D. (2005) Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-Dopa delivery using rAAV vectors. Brain, 128, 559-569.
9. Carta, A.R., Lucia, F., Annalisa, P., Silvia, P., Nicola, S., Nicoletta, S. & Micaela, M. (2008) Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Synapse, 62, 524-533.
10. Cenci, M.A. (2007) Advances in understanding L-Dopa-induced dyskinesia. Curr. Opin. Neurobiol., 17, 665-671.
11. Cenci, M.A. & Ohlin, K.E. (2009) Rodent models of treatment-induced motor complications in Parkinson's disease. Parkinsonism Relat. Disord., 15(Suppl 4), S13-S17.
12. Cenci, M.A., Lee, C.S. & Bjorklund, A. (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci., 10, 2694-2706.
13. Curran, M.P. & Perry, C.M. (2004) Cabergoline: a review of its use in the treatment of Parkinson's disease. Drugs, 64, 2125-2141.
14. Delfino, M.A., Stefano, A.V., Ferrario, J.E., Taravini, I.R.E., Murer, M.G. & Gershanik, O.S. (2004) Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias. Behav. Brain Res., 152, 297-306.
15. Di Chiara, G., Morelli, M., Barone, P. & Pontieri, F. (1992) Priming as a model of behavioural sensitization. Dev. Pharmacol. Ther., 18, 223-227.
16. Dupre, K.B., Eskow, K.L., Steiniger, A., Klioueva, A., Negron, G.E., Lormand, L., Park, J.Y. & Bishop, C. (2008) Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-Dopa-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology (Berl.), 199, 99-108.
17. Eskow, K.L., Gupta, V., Alam, S., Park, J.Y. & Bishop, C. (2007) The partial 5-HT1A agonist buspirone reduces the expression and development of L-Dopa-induced dyskinesia in rats and improves L-Dopa efficacy. Pharmacol. Biochem. Behav., 87, 306-314.
18. Gomez-Mancilla, B. & Bedard, P.J. (1991) Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated monkeys. J. Pharmacol. Exp. Ther., 259, 409-413.
19. Hattori, N. (2003) Appropriate dosing of pergolide in monotherapy and adjunctive therapy in Parkinson's disease. Curr. Opin. Neurol, 16(Suppl 1), S21-S25.
20. Hauser, R.A., Rascol, O., Korczyn, A.D., Jon, S.A., Watts, R.L., Poewe, W., De Deyn, P.P. & Lang, A.E. (2007) Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov. Disord., 22, 2409-2417.
21. Higgins, D.S. Jr (2001) Chorea and its disorders. Neurol. Clin., 19, 707-722, vii.
22. Inzelberg, R., Schechtman, E. & Nisipeanu, P. (2003) Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs Aging, 20, 847-855.
23. Jackson, M.J., Smith, L.A., Al-Barghouthy, G., Rose, S. & Jenner, P. (2007) Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Exp. Neurol., 204, 162-170.
24. Jenner, P. (2009) From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease. Parkinsonism Relat. Disord., 15(Suppl 4), S18-S23.
25. Jenner, P. & Tulloch, T. (1997) The preclinical pharmacology of ropinirole - receptor interactions, antiparkinsonian activity and potential to induce dyskinesia. In Olanow, C.W. & Obeso, J.A. (Eds), Beyond the Decade of the Brain - Dopamine Agonists in Early Parkinson's Disease, Vol. 2. Wells Medical Limited, Royal Tunbridge Wells, pp. 115-128.
26. Korczyn, A.D., Brooks, D.J., Brunt, E.R., Poewe, W.H., Rascol, O. & Stocchi, F. (1998) Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov. Disord., 13, 46-51.
27. Kuan, W.L., Zhao, J.W. & Barker, R.A. (2008) The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Psychopharmacology (Berl.), 197, 279-293.
28. Lane, E.L. & Dunnett, S.B. (2010) Pre-treatment with dopamine agonists influence l-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat. Behav. Brain Res., 213, 66-72.
29. Larramendy, C., Taravini, I.R.E., Saborido, M.D., Ferrario, J.E., Murer, M.G. & Gershanik, O.S. (2008) Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism. Behav. Brain Res., 194, 44-51.
30. Lindgren, H.S., Andersson, D.R., Lagerkvist, S., Nissbrandt, H. & Cenci, M.A. (2009) L-Dopa-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem., 112, 1465-1476.
31. Lundblad, M., Andersson, M., Winkler, C., Kirik, D., Wierup, N. & Cenci, M.A. (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci., 15, 120-132.
32. Maratos, E.C., Jackson, M.J., Pearce, R.K. & Jenner, P. (2001) Antiparkinsonian activity and dyskinesia risk of ropinirole and L-Dopa combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Mov. Disord., 16, 631-641.
33. Maratos, E.C., Jackson, M.J., Pearce, R.K.B., Cannizzaro, C. & Jenner, P. (2003) Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than -DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp. Neurol., 179, 90-102.
34. Monville, C., Torres, E.M. &Dunnett, S.B. (2005) Validation of the L-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res. Bull., 68, 16-23.
35. Mura, A., Mintz, M. & Feldon, J. (2002) Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system. Exp. Neurol., 177, 252-264.
36. Obeso, J.A., Grandas, F., Herrero, M.T. & Horowski, R. (1994) The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur. J. Neurosci., 6, 889-897.
37. Parkinson Study Group (1993) Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom. BMJ, 307, 469-472.
38. Parkinson Study Group (2009) Long-term effect of initiating pramipexole vs levodopa in early Parkinson Disease. Arch. Neurol., 66, 563-570.
39. Paxinos, G. & Watson, C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
40. Pearce, R.K., Jackson, M., Smith, L., Jenner, P. & Marsden, C.D. (1995) Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov. Disord., 10, 731-740.
41. Pearce, R.K., Banerji, T., Jenner, P. & Marsden, C.D. (1998) De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-Dopa in the MPTP-treated marmoset. Mov. Disord., 13, 234-241.
42. Ramji, J.V., Keogh, J.P., Blake, T.J., Broom, C., Chenery, R.J., Citerone, D.R., Lewis, V.A., Taylor, A.C. & Yeulet, S.E. (1999) Disposition of ropinirole in animals and man. Xenobiotica, 29, 311-325.
43. Rascol, O., Brooks, D.J., Brunt, E.R., Korczyn, A.D., Poewe, W.H. & Stocchi, F. (1998) Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov. Disord., 13, 39-45.
44. Rascol, O., Brooks, D.J., Korczyn, A.D., De Deyn, P.P., Clarke, C.E. & Lang, A.E. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N. Engl. J. Med., 342, 1484-1491.
45. Reavill, C., Boyfield, I., Coldwell, M. & Nelson, P. (2000) Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats. J. Pharm. Pharmacol., 52, 1129-1135.
46. Smith, L.A., Jackson, M.J., Johnston, L., Kuoppamaki, M., Rose, S., Al-Barghouthy, G., Del, S.S. & Jenner, P. (2006) Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clin. Neuropharmacol., 29, 112-125.
47. Stocchi, F. (2009) The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease. Parkinsonism Relat. Disord., 15(Suppl 1), S9-S15.
48. Taylor, J.L., Bishop, C. & Walker, P.D. (2005) Dopamine D1 and D2 receptor contributions to L-Dopa-induced dyskinesia in the dopamine-depleted rat. Pharmacol. Biochem. Behav., 81, 887-893.
49. Truong, L., Allbutt, H., Kassiou, M. & Henderson, J.M. (2006) Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions. Behav. Brain Res., 169, 1-9.
50. Zhang, H., Ma, L., Wang, F., Chen, J. & Zhen, X. (2007) Chronic SKF83959 induced less severe dyskinesia and attenuated L-Dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neuropharmacology, 53, 125-133.